---
document_datetime: 2025-12-21 09:13:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/coagadex.html
document_name: coagadex.html
version: success
processing_time: 0.1154145
conversion_datetime: 2025-12-28 00:51:19.509532
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Coagadex

[RSS](/en/individual-human-medicine.xml/66677)

##### Authorised

This medicine is authorised for use in the European Union

human coagulation factor X Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Coagadex](#news-on)
- [More information on Coagadex](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Coagadex is a medicine used for the treatment and prevention of bleeding (including during and after an operation) in patients with hereditary factor X deficiency. Factor X deficiency is a bleeding disorder caused by lack of factor X, a protein needed for normal clotting of the blood.

Factor X deficiency is rare and Coagadex was designated an 'orphan medicine' (a medicine used in rare diseases) on 14 September 2007. Further information on the orphan designation can be found on [EU/3/07/471](/en/medicines/human/orphan-designations/eu-3-07-471) page.

Coagadex contains the active substance human coagulation factor X.

Expand section

Collapse section

## How is Coagadex used?

Coagadex is given by injection into a vein. The dose and frequency of the injections depend on the severity of the patient's factor X deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.

Coagadex can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in the treatment of rare bleeding disorders. Patients may inject Coagadex themselves at home once they have been trained appropriately. For more information about using Coagadex, see the package leaflet or contact your doctor or pharmacist.

## How does Coagadex work?

Patients with hereditary factor X deficiency lack factor X, a protein needed to form the blood clot that stops wounds from bleeding. In these patients, blood clots do not form properly, resulting in bleeding that does not stop easily and poor wound healing. The active substance in Coagadex is human factor X isolated from the plasma of blood donors. By replacing the missing factor X, Coagadex helps the blood to clot and gives temporary control of bleeding.

## What benefits of Coagadex have been shown in studies?

Coagadex has been investigated in one main study involving 16 patients with hereditary factor X deficiency aged 12 to 58 years. Patients received Coagadex either to treat any spontaneous bleeding during the treatment period or to prevent bleeding during surgery. The main measure of effectiveness was based on the doctor's and patient's assessment of how well the treatment worked in preventing and treating bleeding episodes.

For the treatment of bleeding, 187 bleeding episodes were recorded and assessed, and treatment with Coagadex was rated as 'excellent' or 'good' for 98.4% of bleeding episodes. For 3 minor surgeries during the study, Coagadex was rated as excellent in preventing bleeding episodes.

In a study with 9 children aged less than 12 years (4 of whom were under4 years of age), a routine preventive treatment with Coagadex over 6 months was rated as excellent in reducing or preventing bleeding episodes. In total, 10 bleeds were reported in the study, of which 4 were treated with Coagadex. A single infusion of Coagadex was sufficient to control each treated bleeding event.

## What are the risks associated with Coagadex?

The most common side effects with Coagadex (which may affect up to 1 in 10 people) are pain or redness at the injection site, fatigue (tiredness), and back pain.

Hypersensitivity (allergic) reactions can occur rarely in patients treated for bleeding disorders (in up to 1 patient in 1,000) and can be severe in some cases. These reactions have not been reported during clinical studies with Coagadex.

For the full list of side effects and restrictions with Coagadex, see the package leaflet.

## Why is Coagadex authorised in the EU?

The European Medicines Agency decided that the benefits of Coagadex are greater than its risks and it can be authorised for use in the EU. The Agency considered the lack of specific therapies for factor X deficiency, and concluded that Coagadex was effective at treating and preventing bleeding in patients with the condition. The side effects of Coagadex were considered manageable and of mild or moderate intensity. However, given the extreme rarity of the condition, the safety database is small and rare events are not expected to be captured during the clinical studies.

## What measures are being taken to ensure the safe and effective use of Coagadex?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Coagadex have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Coagadex are continuously monitored. Side effects reported with Coagadex are carefully evaluated and any necessary action taken to protect patients.

## Other information about Coagadex

Coagadex received a marketing authorisation valid throughout the EU on 16 March 2016.

Coagadex : EPAR - Medicine overview

English (EN) (76.9 KB - PDF)

**First published:** 04/04/2016

**Last updated:** 07/11/2018

[View](/en/documents/overview/coagadex-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-242)

български (BG) (109.09 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/bg/documents/overview/coagadex-epar-medicine-overview_bg.pdf)

español (ES) (76.32 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/es/documents/overview/coagadex-epar-medicine-overview_es.pdf)

čeština (CS) (100.47 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/cs/documents/overview/coagadex-epar-medicine-overview_cs.pdf)

dansk (DA) (75.27 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/da/documents/overview/coagadex-epar-medicine-overview_da.pdf)

Deutsch (DE) (77.17 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/de/documents/overview/coagadex-epar-medicine-overview_de.pdf)

eesti keel (ET) (74.48 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/et/documents/overview/coagadex-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.34 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/el/documents/overview/coagadex-epar-medicine-overview_el.pdf)

français (FR) (76.7 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/fr/documents/overview/coagadex-epar-medicine-overview_fr.pdf)

hrvatski (HR) (97.72 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/hr/documents/overview/coagadex-epar-medicine-overview_hr.pdf)

italiano (IT) (76.33 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/it/documents/overview/coagadex-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (106.07 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/lv/documents/overview/coagadex-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (108.53 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/lt/documents/overview/coagadex-epar-medicine-overview_lt.pdf)

magyar (HU) (95.91 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/hu/documents/overview/coagadex-epar-medicine-overview_hu.pdf)

Malti (MT) (101.7 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/mt/documents/overview/coagadex-epar-medicine-overview_mt.pdf)

Nederlands (NL) (75.77 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/nl/documents/overview/coagadex-epar-medicine-overview_nl.pdf)

polski (PL) (108.42 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/pl/documents/overview/coagadex-epar-medicine-overview_pl.pdf)

português (PT) (76.56 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/pt/documents/overview/coagadex-epar-medicine-overview_pt.pdf)

română (RO) (91.62 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/ro/documents/overview/coagadex-epar-medicine-overview_ro.pdf)

slovenčina (SK) (107.6 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/sk/documents/overview/coagadex-epar-medicine-overview_sk.pdf)

slovenščina (SL) (94.94 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/sl/documents/overview/coagadex-epar-medicine-overview_sl.pdf)

Suomi (FI) (75.22 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/fi/documents/overview/coagadex-epar-medicine-overview_fi.pdf)

svenska (SV) (75.96 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

07/11/2018

[View](/sv/documents/overview/coagadex-epar-medicine-overview_sv.pdf)

Coagadex : EPAR - Risk-management-plan summary

English (EN) (126.84 KB - PDF)

**First published:** 09/04/2021

[View](/en/documents/rmp-summary/coagadex-epar-risk-management-plan-summary_en.pdf)

## Product information

Coagadex : EPAR - Product Information

English (EN) (340.86 KB - PDF)

**First published:** 04/04/2016

**Last updated:** 15/12/2025

[View](/en/documents/product-information/coagadex-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-247)

български (BG) (363.79 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/bg/documents/product-information/coagadex-epar-product-information_bg.pdf)

español (ES) (314.99 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/es/documents/product-information/coagadex-epar-product-information_es.pdf)

čeština (CS) (392.11 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/cs/documents/product-information/coagadex-epar-product-information_cs.pdf)

dansk (DA) (319.52 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/da/documents/product-information/coagadex-epar-product-information_da.pdf)

Deutsch (DE) (330.66 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/de/documents/product-information/coagadex-epar-product-information_de.pdf)

eesti keel (ET) (227.77 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/et/documents/product-information/coagadex-epar-product-information_et.pdf)

ελληνικά (EL) (480.06 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/el/documents/product-information/coagadex-epar-product-information_el.pdf)

français (FR) (344 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/fr/documents/product-information/coagadex-epar-product-information_fr.pdf)

hrvatski (HR) (380.85 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/hr/documents/product-information/coagadex-epar-product-information_hr.pdf)

íslenska (IS) (338.24 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/is/documents/product-information/coagadex-epar-product-information_is.pdf)

italiano (IT) (328.64 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/it/documents/product-information/coagadex-epar-product-information_it.pdf)

latviešu valoda (LV) (396.29 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/lv/documents/product-information/coagadex-epar-product-information_lv.pdf)

lietuvių kalba (LT) (388.88 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/lt/documents/product-information/coagadex-epar-product-information_lt.pdf)

magyar (HU) (412.45 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/hu/documents/product-information/coagadex-epar-product-information_hu.pdf)

Malti (MT) (342.77 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/mt/documents/product-information/coagadex-epar-product-information_mt.pdf)

Nederlands (NL) (226.38 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/nl/documents/product-information/coagadex-epar-product-information_nl.pdf)

norsk (NO) (310.65 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/no/documents/product-information/coagadex-epar-product-information_no.pdf)

polski (PL) (402.78 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/pl/documents/product-information/coagadex-epar-product-information_pl.pdf)

português (PT) (323.43 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/pt/documents/product-information/coagadex-epar-product-information_pt.pdf)

română (RO) (484.23 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/ro/documents/product-information/coagadex-epar-product-information_ro.pdf)

slovenčina (SK) (390.28 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/sk/documents/product-information/coagadex-epar-product-information_sk.pdf)

slovenščina (SL) (298.71 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/sl/documents/product-information/coagadex-epar-product-information_sl.pdf)

Suomi (FI) (230.79 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/fi/documents/product-information/coagadex-epar-product-information_fi.pdf)

svenska (SV) (313.74 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

15/12/2025

[View](/sv/documents/product-information/coagadex-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0000302442 21/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Coagadex : EPAR - All Authorised presentations

English (EN) (26.65 KB - PDF)

**First published:** 04/04/2016

**Last updated:** 04/04/2016

[View](/en/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-291)

български (BG) (74.68 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/bg/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.38 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/es/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.03 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/cs/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.66 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/da/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.01 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/de/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.29 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/et/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.08 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/el/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_el.pdf)

français (FR) (27.92 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/fr/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (42.64 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/hr/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.05 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/is/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.53 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/it/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.71 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/lv/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.51 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/lt/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.9 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/hu/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.95 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/mt/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.55 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/nl/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.52 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/no/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.46 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/pl/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.84 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/pt/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.22 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/ro/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (41.45 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/sk/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.03 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/sl/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.01 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/fi/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.63 KB - PDF)

**First published:**

04/04/2016

**Last updated:**

04/04/2016

[View](/sv/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Coagadex Active substance human coagulation factor X International non-proprietary name (INN) or common name human coagulation factor X Therapeutic area (MeSH) Factor X Deficiency Anatomical therapeutic chemical (ATC) code B02BD13

### Pharmacotherapeutic group

- Vitamin K and other hemostatics
- Antihemorrhagics
- coagulation factor X

### Therapeutic indication

Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups.

## Authorisation details

EMA product number EMEA/H/C/003855

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Kedrion S.p.A.

Castelvecchio Pascoli Localita Ai Conti Snc Barga LU 55051 Italy

Opinion adopted 28/01/2016 Marketing authorisation issued 16/03/2016 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Coagadex : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.34 KB - PDF)

**First published:** 04/03/2025

**Last updated:** 15/12/2025

[View](/en/documents/procedural-steps-after/coagadex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Coagadex : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (157.54 KB - PDF)

**First published:** 07/11/2018

**Last updated:** 04/03/2025

[View](/en/documents/procedural-steps-after/coagadex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Coagadex : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/511316/2018

English (EN) (62.82 KB - PDF)

**First published:** 07/11/2018

[View](/en/documents/pip-compliance/coagadex-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Coagadex : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/455550/2018

English (EN) (1.94 MB - PDF)

**First published:** 07/11/2018

[View](/en/documents/variation-report/coagadex-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Coagadex : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/139881/2016

English (EN) (2.18 MB - PDF)

**First published:** 04/04/2016

**Last updated:** 04/04/2016

[View](/en/documents/assessment-report/coagadex-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Coagadex

Adopted

Reference Number: EMA/CHMP/15062/2016

English (EN) (75.08 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 29/01/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-coagadex_en.pdf)

#### News on Coagadex

[First specific replacement therapy to treat rare bleeding disorder](/en/news/first-specific-replacement-therapy-treat-rare-bleeding-disorder) 29/01/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-january-2016) 29/01/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0038550000) (initial marketing authorisation)

#### More information on Coagadex

- [EU/3/07/471 - orphan designation for treatment of hereditary factor X deficiency](/en/medicines/human/orphan-designations/eu-3-07-471)
- [EMEA-000971-PIP01-10-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000971-pip01-10-m03)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/12/2025

## Share this page

[Back to top](#main-content)